EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency

Gaurav Baranwal iD, Haseeb Mukhtar iD, Jamie Kane iD, Alaura Lemieux, Sanjay Misra

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252312719 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Gaurav Baranwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) affects more than 10% of the world’s population. Hemodialysis, along with peritoneal dialysis and renal transplant, is one of the renal replacement therapies offered to patients with CKD/end-stage renal disease (ESRD). To proceed with hemodialysis, vascular access is required. The two means of long-term access are arteriovenous fistula (AVF) and arteriovenous graft (AVG). Multiple therapies have been created to help the long-term patency of AVFs. These therapies are needed as 40% of AVFs fail within the first year and additional intervention is required. Much of the existing research has focused on biomarkers, immune cells, hypoxia, and cell-based therapies. Regeneration therapy using mesenchymal stem cells seeks to investigate other ways that we can treat AVF failure. Mesenchymal stem cells are harvested as two main types, fetal and adult. Fetal cells are harvested at different times in fetal gestation and from multiple sources, placental blood, Whartons jelly, and amniotic stem cell fluid. Taken together, this review summarizes the different preclinical/clinical studies conducted using different types of MSCs towards vascular regenerative medicine and further highlights its potential to be a suitable alternative approach to enhance AVF patency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem Cell TransplantationMesenchymal Stem CellsHumansRenal DialysisArteriovenous FistulaAnimalsVascular PatencyArteriovenous Shunt, SurgicalRenal Insufficiency, ChronicKidney Failure, ChronicCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

arteriovenous fistulasmesenchymal stem cellsstenosis and restenosisvascular remodeling

Autor:innen und Institutionen

  • Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Gaurav Baranwal, Haseeb Mukhtar, Jamie Kane

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • NIH HHS
  • NIH
  • Minnesota Regenerative Medicine

Zitieren

APA

Baranwal, G., Mukhtar, H., Kane, J., Lemieux, A., & Misra, S. (2024). Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312719

Vancouver

Baranwal G, Mukhtar H, Kane J, Lemieux A, Misra S. Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312719

BibTeX
@article{Baranwal2024,
  author = {Baranwal, Gaurav and Mukhtar, Haseeb and Kane, Jamie and Lemieux, Alaura and Misra, Sanjay},
  title = {Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252312719}
}
Kostenlos starten →